Drugs.com - Clinical Trials

Zydus Announces USFDA Orphan Drug Designation to Usnoflast for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Zydus Announces USFDA Orphan Drug Designation to Usnofl...

Feb 9, 2025 0

Ahmedabad, India, January 22, 2025 Zydus, a leading, discovery-based, global pha...

Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy

Alterity Therapeutics Announces Positive ATH434 Phase 2...

Feb 9, 2025 0

MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 30 January 2025: Alterity Therape...

Merck Announces Phase 3 waveLINE-010 Trial Initiation Evaluating Zilovertamab Vedotin, an Investigational Antibody-Drug Conjugate, for the Treatment of Patients With Previously Untreated Diffuse Large B-Cell Lymphoma

Merck Announces Phase 3 waveLINE-010 Trial Initiation E...

Feb 9, 2025 0

RAHWAY, N.J.--(BUSINESS WIRE) February 6, 2025 -- Merck (NYSE: MRK), known as M...

Pila Pharma Announces XEN-D0501 Preclinical Proof-of-Concept Achieved In Cardiovascular Disease Study

Pila Pharma Announces XEN-D0501 Preclinical Proof-of-Co...

Feb 9, 2025 0

Malmö, Sweden 18 December 2024 PILA PHARMA AB (publ) (“PILA PHARMA” or the “Comp...

Genentech’s Phase IIb Study of Prasinezumab Missed Primary Endpoint, but Suggests Possible Benefit in Early-Stage Parkinson’s Disease

Genentech’s Phase IIb Study of Prasinezumab Missed Prim...

Feb 9, 2025 0

South San Francisco, CA -- December 18, 2024 -- Genentech, a member of the Roche...

$Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom’s Macroglobulinemia$

Nurix Therapeutics Receives U.S. FDA Fast Track Designa...

Feb 9, 2025 0

SAN FRANCISCO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasda...

Sapience Therapeutics Receives FDA Orphan Drug Designation for ST316, a First-in-Class β-catenin Antagonist, for the Treatment of Familial Adenomatous Polyposis (FAP)

Sapience Therapeutics Receives FDA Orphan Drug Designat...

Feb 9, 2025 0

TARRYTOWN, N.Y., December 19, 2024 – Sapience Therapeutics, Inc., a clinical-sta...

Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy

Vertex Announces Results From Phase 2 Study of Suzetrig...

Feb 9, 2025 0

BOSTON--(BUSINESS WIRE)--Dec. 19, 2024-- Vertex Pharmaceuticals Incorporated (Na...

LimmaTech Awarded FDA Fast Track Designation for Vaccine Candidate Against Staphylococcus aureus

LimmaTech Awarded FDA Fast Track Designation for Vaccin...

Feb 9, 2025 0

SCHLIEREN, Switzerland--(BUSINESS WIRE)-- December 19, 2024 LimmaTech Biologics ...

CagriSema Demonstrates Superior Weight Loss in Adults with Obesity or Overweight in the REDEFINE 1 Trial

CagriSema Demonstrates Superior Weight Loss in Adults w...

Feb 9, 2025 0

Bagsværd, Denmark, 20 December 2024 – Novo Nordisk today announced headline resu...

Axsome Therapeutics Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer’s Disease Agitation

Axsome Therapeutics Announces Successful Completion and...

Feb 9, 2025 0

NEW YORK, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: A...

NIH Researchers Discover Novel Class of Anti-Malaria Antibodies

NIH Researchers Discover Novel Class of Anti-Malaria An...

Feb 9, 2025 0

January 3, 2025 -- A novel class of antibodies that binds to a previously untarg...

Gradalis’ GRAD1405 bi-shRNAi Candidate First to Show Positive Impact on Three Key KRAS Mutations Identified in Drug Resistant Lung, Colon and Pancreatic Cancers

Gradalis’ GRAD1405 bi-shRNAi Candidate First to Show Po...

Feb 9, 2025 0

DALLAS, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Gradalis Inc., a clinical-stage biotec...

Vergent Bioscience Receives FDA Fast Track Designation for Abenacianine for Injection (VGT-309) to Help Surgeons Visualize Tumors in the Lung During Surgery

Vergent Bioscience Receives FDA Fast Track Designation ...

Feb 9, 2025 0

MINNEAPOLIS, Minn., January 7, 2025 – Vergent Bioscience, a clinical-stage biote...

Mineralys Therapeutics Announces Phase 2 Clinical Trial of Lorundrostat for Obstructive Sleep Apnea in Patients with Hypertension

Mineralys Therapeutics Announces Phase 2 Clinical Trial...

Feb 9, 2025 0

RADNOR, Pa., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nas...

Johnson & Johnson’s Posdinemab and Tau Active Immunotherapy Receive U.S. FDA Fast Track Designations for the Treatment of Alzheimer’s Disease

Johnson & Johnson’s Posdinemab and Tau Active Immunothe...

Feb 9, 2025 0

TITUSVILLE, N.J., January 8, 2025 -- Johnson & Johnson (NYSE: JNJ) announced tod...

Nipocalimab Granted U.S. FDA Priority Review for the Treatment of Generalized Myasthenia Gravis

Nipocalimab Granted U.S. FDA Priority Review for the Tr...

Feb 9, 2025 0

SPRING HOUSE, Pa., (January 9, 2025) – Johnson & Johnson (NYSE: JNJ) today annou...

Research and Pipeline Research Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer

Research and Pipeline Research Pfizer’s Sasanlimab in C...

Feb 9, 2025 0

NEW YORK--(BUSINESS WIRE)-- January 10, 2025 -- Pfizer Inc. (NYSE: PFE) today a...

Crinetics Announces Positive Topline Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)

Crinetics Announces Positive Topline Results From Phase...

Feb 9, 2025 0

SAN DIEGO – January 10, 2025 – Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) to...

Mersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660)

Mersana Therapeutics Announces Additional FDA Fast Trac...

Feb 9, 2025 0

CAMBRIDGE, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (...

Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

Dyne Therapeutics Receives FDA Fast Track Designation f...

Feb 9, 2025 0

WALTHAM, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasda...

Humanetics Corporation Announces Positive Phase 2 Clinical Trial Results in COVID-19 Study Aimed at Improving Pulmonary Function

Humanetics Corporation Announces Positive Phase 2 Clini...

Feb 9, 2025 0

MINNEAPOLIS, MN -- January 22, 2025 -- Humanetics Corporation (Humanetics) annou...

Amylyx Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on AMX0114 Phase 1 Clinical Trial for the Treatment of Amyotrophic Lateral Sclerosis

Amylyx Pharmaceuticals Announces FDA Has Lifted the Cli...

Feb 9, 2025 0

CAMBRIDGE, Mass.-- January 21, 2025 (BUSINESS WIRE)-- Amylyx Pharmaceuticals, I...

Boehringer Provides Update on Iclepertin Phase III Program in Schizophrenia

Boehringer Provides Update on Iclepertin Phase III Prog...

Feb 9, 2025 0

Ingelheim, Germany, January 16, 2025 - Boehringer Ingelheim today announced top-...

1
2
3

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.